Articles Related to ACOG
Pharmacy Compounding Quality Control and Pharmaceutical Development Strategies for Seventeen alpha Hydroxyprogesterone Caproate in Prevention of Preterm Delivery
Seventeen alpha hydroxyprogesterone caproate (17-OHPC) is the only FDA-approved drug labeled for prevention of preterm delivery. This drug is also available as a compounded product from licensed compounding pharmacies. This article reviews the FDA approval history and pharmacy compounding quality control data of 17-OHPC, as well as briefly discusses possible future pharmaceutical development strategies for 17-OHPC.
Editorial Board Members Related to ACOG
Bassam R. Ali
Professor
Department of Pathology
College of Medicine and Health Sciences
UAE University
United Arab Emirates
Department of Pathology
College of Medicine and Health Sciences
UAE University
United Arab Emirates
David Ilki Min
Professor
Pharmacy Practice and Administration
Western University of Health Sciences
United States
Pharmacy Practice and Administration
Western University of Health Sciences
United States
Eyad Mazin Mallah
Associate professor
Department of Pharmaceutical Medicinal Chemistry and Pharmacognosy
University of Petra
Jordan
Department of Pharmaceutical Medicinal Chemistry and Pharmacognosy
University of Petra
Jordan
Richard Lobo
Associate Professor
Department of Pharmacognosy
Manipal College of Pharmaceutical Sciences
India
Department of Pharmacognosy
Manipal College of Pharmaceutical Sciences
India
Alain L Fymat
President/CEO and Professor
International Institute of Medicine and Science
Rancho Mirage
California
USA
International Institute of Medicine and Science
Rancho Mirage
California
USA
Rathnayake Mudiyanselage Dharmadasa
Senior Deputy Director
Industrial Technology Institute
Sriparakum Mawatha
Sri Lanka
Industrial Technology Institute
Sriparakum Mawatha
Sri Lanka